Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
Status:
Not yet recruiting
Trial end date:
2036-11-01
Target enrollment:
Participant gender:
Summary
This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects
will be enrolled. The "3+3" dose escalation design is adopted. The main purpose is to
evaluate the safety of RD133 in the treatment of subjects with relapsed or refractory
MSLN-positive solid tumors and explore the Recommend phase II dose of RD133 in the treatment
of patients with relapsed/refractory MSLN-positive solid tumors.